Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
तुलना करने के लिए मीट्रिक्स | IPCIF | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIPCIFपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.6x | −5.4x | −0.6x | |
PEG अनुपात | 0.00 | −0.04 | 0.00 | |
क़ीमत/बुक | −0.2x | 1.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.2x | 2.1x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 0.0% | 48.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.9% | 6.8% | अनलॉक करें |